On ECHEMI
Home > Drugs > Ovarian cancer
Ovarian cancer
Ovarian cancer is one of the common tumors of female reproductive organs, and its incidence rate ranks third after cervical cancer and uterine body cancer. However, deaths caused by ovarian cancer account for the first place among all kinds of gynecological tumors, posing a serious threat to women's lives. Due to the complex embryonic development, tissue anatomy and endocrine function of the ovaries, the tumors it suffers from may be benign or malignant. Since ovarian cancer has no symptoms in the early clinical stage, it is quite difficult to distinguish its tissue type and benign or malignant. During laparotomy for ovarian cancer, only 30% of the tumors are found to be confined to the ovaries, and most of them have spread to the uterus, bilateral adnexa, greater omentum and pelvic organs. Therefore, ovarian cancer is indeed a big problem in both diagnosis and treatment. Over the years, experts have conducted many discussions on the pathological morphology, clinical occurrence and development rules and treatment plans of ovarian malignant tumors, and accumulated a lot of experience. So far, according to clinical data statistics at home and abroad, its five-year survival rate is only 25% to 30%.
Related Drugs
Cisplatin Sodium Chloride Injection
Indication: It is the first-line drug for the treatment of various solid tumors; it is the first-line treatment for SCLC or NSCLC when combined with VP-16 (EP regimen); it is the commonly used regimen for the treatment of NSCLC when combined with MMC, IFO (IMP regimen), or NVB. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. It is effective in combination with ADM, CTX, etc. for squamous cell carcinoma and transitional cell carcinoma in multiple parts, such as head and neck, cervix, esophagus and urinary system tumors; "PVB" (DDP, VLB, BLM) can treat most stage IV non-spermogenic testicular cancers, with a remission rate of 50% to 80%; in addition, this product is a radiosensitizer and is currently widely used abroad for local treatment of stage IV inoperable NSCLC
Vinorelbine tartrate injection
Indication: It is clinically used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphadenopathy, etc.
Manufacturer:

Nanjing Cuccess Pharmaceutical Co., Ltd.

Vinorelbine Bitartrate for Injection
Indication: Anti-tumor drug used for non-small cell lung cancer, breast cancer, refractory lymphoma, ovarian cancer, etc.
Manufacturer:

Hainan Tongyong Kangli Pharmaceutical Co., Ltd.

Vinorelbine Bitartrate for Injection
Indication: Anti-tumor drug used for non-small cell lung cancer, breast cancer, refractory lymphoma, ovarian cancer, etc.
Vinorelbine Bitartrate for Injection
Indication: Anti-tumor drug used for non-small cell lung cancer, breast cancer, refractory lymphoma, ovarian cancer, etc.
Vinorelbine tartrate injection
Indication: It is clinically used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphadenopathy, etc.
Manufacturer:

Han Hui Pharmaceuticals Company Limited

Hexamethylmelamine tablets
Indication: This product is used for combined chemotherapy of ovarian cancer, SCLC, malignant lymphoma, and endometrial cancer, and is particularly effective for ovarian cancer and SCLC.
Hexamethylmelamine tablets
Indication: This product is used for combined chemotherapy of ovarian cancer, SCLC, malignant lymphoma, and endometrial cancer, and is particularly effective for ovarian cancer and SCLC.
Manufacturer:

Sunflower Pharmaceutical Group (Yichun) Co., Ltd.

Hexamethylmelamine tablets
Indication: This product is used for combined chemotherapy of ovarian cancer, SCLC, malignant lymphoma, and endometrial cancer, and is particularly effective for ovarian cancer and SCLC.
Manufacturer:

Nanyang Pukang Hengwang Pharmaceutical Co., Ltd.

Hexamethylmelamine capsules
Indication: This product is used for combined chemotherapy of ovarian cancer, SCLC, malignant lymphoma, and endometrial cancer, and is particularly effective for ovarian cancer and SCLC.
Manufacturer:

ZHONGFU Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.